Geng 2022 pooled 15 randomized controlled trials and found sea buckthorn significantly improved blood lipids: triglycerides, total cholesterol, and LDL down, HDL up, with the effect driven by participants who started with abnormal levels. The same analysis found no significant effect on fasting glucose, blood pressure, or BMI. This page gives both halves equal weight, because the nulls are what make the positives believable.
What pooling 15 trials actually means
A meta-analysis averages many small trials into one estimate, trading each study’s noise for a shared signal. Fifteen trials is a decent pool for a supplement, and pooling matters here because the individual trials were small: alone, each could be dismissed as a fluke. Together, they either converge on a real effect or on a shared bias, which is why the corroboration below matters.
The positives, and who drove them
Four lipid markers moved significantly: triglycerides down, total cholesterol down, LDL down, HDL up.
The subgroup finding is the heart of the paper. The significance was driven by participants who entered with abnormal blood lipids. Healthy volunteers with normal levels barely moved. Sea buckthorn behaved like a corrector of abnormal lipids, not an improver of normal ones, and that pattern repeats so consistently across the pool that it shapes our advice on the cholesterol page: normal labs, no reason to bother.
The subgroup logic, and why it matters for you
The corrector-not-improver pattern is the single most useful sentence in the paper, because it tells you which reader you are. It also has an independent echo. In a crossover trial comparing sea buckthorn with bilberry in overweight women, the effects differed by each woman’s baseline metabolic profile: the same berry did different things depending on who swallowed it. That is one small study, not a confirmation, and it points the same direction as the pooled subgroups. Baseline biology shapes the response, which is why the heart hub routes people by their labs rather than by their hopes.
The nulls, printed in the same size
The same 15-trial pool found no significant effect on:
- Fasting blood glucose
- Blood pressure
- BMI and body weight
These are not footnotes. They are the same analysis, the same methods, the same statistical power, answering three other questions with “no.” Any page or label quoting the lipid half of Geng 2022 without the null half is clipping the paper to fit a sales pitch. Our metabolic health page maps all four outcomes marker by marker.
The numbers in everyday terms
A pooled lipid shift is a lab report, not a life outcome, and the translation matters. Picture two readers. The first has normal cholesterol and normal triglycerides: the subgroup analysis says the likely pooled effect for them hovers near zero, and no amount of capsule loyalty changes that. The second has abnormal lipids their doctor is already watching: the trials say twelve weeks of oil moved the panel in the right direction, on average, by amounts a lipid clinic would call modest. Modest marker shifts compound into risk changes slowly, if at all, and no sea buckthorn trial has ever counted a heart attack prevented. The same logic governs the triglyceride result: it is a number on a fasting lab draw, valuable as a trend line, silent as a guarantee.
The quality caveats, because they travel with the numbers
- Small trials. The pooled studies were modest in size, which is normal for supplements and limiting everywhere.
- Short durations. Weeks to a few months. Nothing here speaks to years of use.
- Markers, not events. Cholesterol numbers predict risk, but they are not heart attacks or strokes. No trial has followed sea buckthorn users to actual cardiovascular events.
- Heterogeneity. Doses, oil types, and populations varied across the 15 trials, so the pooled estimate averages over real differences.
Heterogeneity deserves one more paragraph, because it is where the pooled average can mislead. Across the 15 trials, doses ran roughly 1.5 to 3 grams, the oils were seeds, berries, or blends, and the participants ranged from healthy volunteers to people with abnormal lipids. The meta-analysis handles that statistically, and the subgroup finding survived it, but a pooled estimate is still an average over genuinely different experiments.
Why the 2017 meta-analysis doubles the grade
Five years earlier, Guo 2017 pooled 11 independent randomized trials on blood lipids and reached the same conclusions from a different set of studies. Two research groups, two pools, one direction. Independent convergence is exactly what moves a finding from “interesting” to “strongest evidence this plant has,” and it is why this page carries our top grade while remaining, in absolute terms, a supplement evidence base rather than a drug trial program. The practical doses behind the pooled trials are tabulated on the study dosages page, and every other human trial sits in the clinical trials catalog.
How this site spends that grade
Strong for lipid markers means three things here and only three. The cholesterol page may say the evidence supports a modest improvement for people with abnormal levels. The blood pressure page may not borrow the grade, because the pool said no. And the weight loss page may not borrow it either, because the BMI null was found with the same power as the lipid positive. One analysis, four answers, each honored at full strength.
What would settle this
The definitive study would enroll thousands of people with abnormal lipids, follow them for years, and count cardiovascular events rather than lab panels. No supplement maker has ever funded a trial like that, for any supplement, so the realistic hope is narrower: a 12-month trial with abnormal-baseline participants, pre-registered lipid endpoints, and a follow-up after stopping to see whether the shift persists. Until either exists, the honest claim ends at marker improvements over weeks, and the reading-studies page shows how to spot anyone claiming more.
Frequently asked questions
What did the 2022 sea buckthorn meta-analysis find?
Pooling 15 randomized controlled trials, it found sea buckthorn supplementation significantly reduced triglycerides, total cholesterol, and LDL cholesterol while raising HDL, with effects strongest in participants who started with abnormal blood lipids. It found no significant effect on fasting blood glucose, blood pressure, or BMI.
How strong is the sea buckthorn cholesterol evidence?
The strongest this plant has. Two independent meta-analyses (15 trials in 2022, 11 trials in 2017) reached the same lipid conclusions from different pools of studies. The caveats are structural: the underlying trials are small, last weeks rather than years, and measure lab numbers rather than heart attacks or strokes. We grade it strong for lipid markers, not for outcomes.
If it lowers cholesterol, why not blood pressure too?
Because they are different physiology, and markers move independently. Cholesterol synthesis and transport respond to dietary fats and plant compounds; blood pressure is governed by vessels, kidneys, and the nervous system. The same 15-trial pool had the statistical power to find a pressure effect and did not, which is why our blood-pressure page carries the null rather than the borrowed hope.